Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, and Phase 1, dose-escalation clinical trial for NNV1 in patients with newly diagnosed high-grade gliomas; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301) for multiple indications in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers NeuroNova, an oncolytic virus platform; and SuperNova platform. Calidi Biotherapeutics, Inc. is headquartered in San Diego, California.